Crizotinib (PF-02341066)

Licensed by Pfizer 製品コードS1068

文献中の引用(68)

カスタマーフィードバック(11)

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

製品安全説明書

c-Met阻害剤の選択性比較

生物活性

製品説明 Crizotinib (PF-02341066)は一種の有効なc-MetとALK阻害剤で、細胞試験でIC50値が11 nMと24 nMです。
靶点
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro試験

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 M3PXZWN6fG:2b4jpZ{BCe3OjeR?= MmX2OFghcA>? NUXGO5Z1TE2VTx?= NInMUVNEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN M3vOTlIyPTd{NUi5
BAF3 NYLOSVNFS3m2b4TvfIlkKEG|c3H5 MorEOFghcA>? MlvKSG1UVw>? M3HQPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= MWeyNVU4OjV6OR?=
BAF3 M1\0SmN6fG:2b4jpZ{BCe3OjeR?= MoTQOFghcA>? NUTEVotvTE2VTx?= MkLzR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= M1j1S|IyPTd{NUi5
Kelly MVrDfZRwfG:6aXOgRZN{[Xl? M160emROW09? MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KHerdHigTWM2OCCxZjCwMlQzKM7:TR?= M4HjNlIyPTd{NUi5
SH-SY5Y M4\OW2N6fG:2b4jpZ{BCe3OjeR?= NXLKZ45qTE2VTx?= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN MWWyNVU4OjV6OR?=
SMS-KCN M2G2eGN6fG:2b4jpZ{BCe3OjeR?= NH\kdGNFVVOR Mn7JR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=> NUTtWVNsOjF3N{K1PFk>
BAF3 M17mVGN6fG:2b4jpZ{BCe3OjeR?= NY\3eI9KPDhiaB?= MV7EUXNQ M2[4ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCWZXytRWxMKHerdHigTWM2OCCxZjCwMlE6KM7:TR?= MV:yNVU4OjV6OR?=
3T3 MlnBSpVv[3Srb36gRZN{[Xl? NV;NdmVrOSCq M2PJUGROW09? MYDJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0> M3fje|IyQDF{NEG0
3T3-E MXzGeY5kfGmxbjDBd5NigQ>? MlmzNUBp NWfxRVR5TE2VTx?= NX;Yc5Y6UW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? MlzLNlE5OTJ2MUS=
A549 Mmj1T4lv[XOnIFHzd4F6 NEjW[GwyKGh? MorxSG1UVw>? NVvIOZExUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDjMW1GXCCtaX7hd4Uh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhUEeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEig{txO NXXkbIpSOjF6MUK0NVQ>
BAF3-BCL M1j6RmZ2dmO2aX;uJGF{e2G7 MoHWNUBp M1v1[2ROW09? NEPzW25KdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP NWD5NY55OjF6MUK0NVQ>
HEK293 MXXGeY5kfGmxbjDBd5NigQ>? NUK2TXB6OSCq MnzKSG1UVw>? NEXU[mxKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP NIXDPFAzOThzMkSxOC=>
HEK293 MmXuSpVv[3Srb36gRZN{[Xl? MlrvNUBp M1jGZWROW09? NU[3No9[UW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch|ryP M2XIXVIyQDF{NEG0
Jurkat NULKUm9mTnWwY4Tpc44hSXO|YYm= M2P4WlEhcA>? MYnEUXNQ Mmf0TY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? M{H6VFIyQDF{NEG0
KARPAS299 MVTLbY5ie2ViQYPzZZk> MmnFNUBp M2D1SGROW09? M37qZWlvcGmkaYTpc44hd2ZiQVzLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MWmyNVgyOjRzNB?=
PAE MnrCSpVv[3Srb36gRZN{[Xl? NXLo[VFCOSCq MYHEUXNQ MXzJcohq[mm2aX;uJI9nKFSUS1KgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwM{m5JO69VQ>? NH34fWUzOThzMkSxOC=>
BAF3 NXn3dFE3TnWwY4Tpc44hSXO|YYm= NVTLfFRoOi1|IHS= MVLEUXNQ M13qXmlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0> MlLrNlM4PDJ{NUK=
KARPAS299 MmHiR5l1d3SxeHnjJGF{e2G7 NEjXZWYzNTNiZB?= M4jaVWROW09? M{fGZ2lEPTB;MD6wOlQzKM7:TR?= Mmn3NlM4PDJ{NUK=
EBC1 NH3JVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXKeIhEPzJiaB?= NWW5PWl6TE2VTx?= M2XtSWlEPTB;MD6wNlMh|ryP NIqzNIgzOzl7M{OyPC=>
HCT116 NYXUPYllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp NWnlNlF3TE2VTx?= NXjQb4twUUN3ME2xOE45OiEQvF2= NIHBNFYzOzl7M{OyPC=>
MCF7 M{WyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHWTXR2PzJiaB?= Mnz1SG1UVw>? MmSyTWM2OD17LkW4JO69VQ>? MX2yN|k6OzN{OB?=
MDA-MB-231 M4HHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHDe4o4OiCq MlvpSG1UVw>? M{DhWmlEPTB;MUCuPEDPxE1? NEfzNmUzOzl7M{OyPC=>
MKN45 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO5O|IhcA>? NWjsUZV7TE2VTx?= MUHJR|UxRTBwMEGzJO69VQ>? NWn3cFlDOjN7OUOzNlg>
NCI-H441 M2TuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK4Vmk4OiCq NG\JZ2VFVVOR NGP5OYpKSzVyPUG3MlI2KM7:TR?= M{[3WVI{QTl|M{K4
NCI-H661 NVPYVmhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT5dFE4OiCq NXf1fHliTE2VTx?= NWDBPHRDUUN3ME2xNU41PyEQvF2= M4L6XFI{QTl|M{K4
SK-MEL-28 NULLfpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKdlczKGh? MoLySG1UVw>? MoXoTWM2OD1zMD65O{DPxE1? M{TvR|I{QTl|M{K4
SKOV3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KyVVczKGh? MULEUXNQ NWjyVIw1UUN3ME2xNk45PSEQvF2= M4LQZlI{QTl|M{K4
SNU5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zrfFczKGh? M3fXdGROW09? M3jxW2lEPTB;MD6wNVYh|ryP M1rpVFI{QTl|M{K4
NCI-H2228 NGnkUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm3NkBp MYrEUXNQ NVPq[ZlsUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? NXXydmZrOjR2M{K5NFk>
NCI-H3122 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPjO|IhcA>? NXfVU2NCTE2VTx?= MWLJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yODhizszN M{H3SFI1PDN{OUC5
NCI-H3122 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrUUZA4OiCq NV3GepdKTE2VTx?= NV;WO2NLUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO MUiyOFQ{OjlyOR?=
NCI-H3122 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HIdVczKGh? NX\KN|dJTE2VTx?= MnLETY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN MW[yOFQ{OjlyOR?=
NIH-3T3 MUXLbY5ie2ViQYPzZZk> M4rCZ|EhcA>? NFfLdoVFVVOR NGPhcpVKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= M4HscFI1PDN{OUC5
NIH-3T3 MYHLbY5ie2ViQYPzZZk> NYW2OoZ3OSCq NFzYVWFFVVOR M1;VTWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? MmPSNlQ1OzJ7MEm=
NIH-3T3 MnL4T4lv[XOnIFHzd4F6 MVexJIg> M3fkUWROW09? NYnWfIgzUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP M3[1NlI1PDN{OUC5
NIH-3T3 NYjIWmllU2mwYYPlJGF{e2G7 M4fWVlEhcA>? MmXWSG1UVw>? NY\QO4VMUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD64OFMh|ryP MoX6NlQ1OzJ7MEm=
NIH-3T3 NUjuWoVDU2mwYYPlJGF{e2G7 NIq1XpQyKGh? Mm\VSG1UVw>? M3\RRWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMEK2JO69VQ>? MXWyOFQ{OjlyOR?=
BAF3 MoW1SpVv[3Srb36gRZN{[Xl? MUO3NkBp M1;NRmROW09? NHyzPGpKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO M{frSlI1PDZ6NkOy
BAF3 M2HVfmN6fG:2b4jpZ{BCe3OjeR?= MUi3NkBp NH7aTGxFVVOR MkXMTWM2OD1yLkm4JO69VQ>? MlrFNlQ1Pjh4M{K=
NIH-3T3 NGjMRWlMcW6jc3WgRZN{[Xl? M3nXblEhcA>? NX7MTpVrUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BHOTF5NFygcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6xOlUh|ryP MYCyOFgyQTFzNh?=
NIH-3T3 NYHt[XVNU2mwYYPlJGF{e2G7 NYDHfIJ{OSCq MmfpTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC52N{ig{txO NXjJdGlIOjR6MUmxNVY>
NIH-3T3 NWPLTnBPU2mwYYPlJGF{e2G7 NUjUfWdPOSCq NVzKPHdxUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP MnSwNlQ5OTlzMU[=
NIH-3T3 MUXLbY5ie2ViQYPzZZk> NG\zNlUyKGh? NUi2[WxYUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= MXKyOFgyQTFzNh?=
KARPAS299 M1u3R2tqdmG|ZTDBd5NigQ>? MmfEPVAhdWmw MlzBSG1UVw>? M17YfGlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:|cHjvdplt[XSrb36g[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>? M37Gd|I1QTByN{Ww
MKN 45 NUn6eJZTU2mwYYPlJGF{e2G7 MknrNUBp NFHzZo5FVVOR MVXJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MX[yOFkxODd3MB?=
A549 M4G1fmN6fG:2b4jpZ{BCe3OjeR?= M4XZV|Q5KGh? NX7IUZZqTE2VTx?= NWjoSZJDUUN3MDDv[kA1NjB6NDFOwG0> NFHub4EzPDlyMEizNC=>
NCI-H1975 NYXGd2ZWS3m2b4TvfIlkKEG|c3H5 MUK0PEBp NWfBbZNRTE2VTx?= MVjJR|UxKG:oIEeuOVUyKM7:TR?= M1GzZ|I1QTByOEOw
NCI-H1993 NUPIe2FbS3m2b4TvfIlkKEG|c3H5 M13OPVQ5KGh? NVe2eIJlTE2VTx?= MkiwTWM2OCCxZjCwMlA3OSEQvF2= NVXMNZFNOjR7MEC4N|A>
NCI-H1993 NF:1bVNCeG:2b4Ppd{BCe3OjeR?= Ml;PNUDPxE1? NH7Uc|UzPCCq NH65WVdFVVOR M{LXZYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NETlb20zPDlyMEizNC=>
NIH-3T3 NIjBbnJEgXSxdH;4bYMhSXO|YYm= MmLZOFghcA>? M33UOWROW09? M2f1R2lEPTBib3[gNE4{PjRizszN NGTiWJgzPDlyMEizNC=>
EBC1 NWfObmRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjtO|IhcA>? MnnBSG1UVw>? MV;JR|UxKG:oIECuNFA3QSEQvF2= NYXlcppbOjR7MEC4N|E>
KARPAS299 NX;SbphET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqOYJtPzJiaB?= M{jpVGROW09? MXzJR|UxKG:oIECuNkDPxE1? NXX2[3ZtOjR7MEC4N|E>
NB1 NHntOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDEPJdZUUN3ME25NU46QCCwTR?= NUPJUW5RW0GQR1XS
NCI-SNU-5 NHTX[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFyNT63OUBvVQ>? MonrV2FPT0WU
SR NUL3XGQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF{Nj6zNUBvVQ>? MXjTRW5ITVJ?
SF539 NX\oS5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon1TWM2OD1{MESuNlQhdk1? NFToV2NUSU6JRWK=
SU-DHL-1 NGXq[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHn[|VKSzVyPUOzOk45OiCwTR?= NVu0[pZYW0GQR1XS
SCC-3 NX3Hb5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTJTWM2OD1|NU[uO|Yhdk1? M2T3UXNCVkeHUh?=
DEL NYLxVYFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3juOmlEPTB;M{[5Mlkhdk1? M{jodXNCVkeHUh?=
CTV-1 NHHxcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTV7Nj60PEBvVQ>? M{fKWHNCVkeHUh?=
EM-2 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17EbWlEPTB;NkCxMlM1KG6P Ml\aV2FPT0WU
MHH-CALL-2 NVPUTnp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZ6Mj61O{BvVQ>? MV;TRW5ITVJ?
KM12 NEmw[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUcJFKSzVyPUewOk46KG6P NH61XYdUSU6JRWK=
KINGS-1 NFK3cGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn0[m9KSzVyPUe0PU44PSCwTR?= MYXTRW5ITVJ?
MEG-01 M2e1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrVOYZKSzVyPUi1O{43PiCwTR?= MVjTRW5ITVJ?
BV-173 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPDTnRKSzVyPUGuNFU6QTdizszN NXPFSlNIW0GQR1XS
LAMA-84 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zWUWlEPTB;MT6zPFI5OiEQvF2= M122OHNCVkeHUh?=
KARPAS-299 M4PneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwNEC4OlEh|ryP NI\1R|ZUSU6JRWK=
K-562 NH;ZZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwN{KyOlkh|ryP MXrTRW5ITVJ?
SK-LMS-1 NXrJ[Jc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwN{[4Olch|ryP MljIV2FPT0WU
MOLT-16 M33ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13hfmlEPTB;MT65OVU4PSEQvF2= MlO0V2FPT0WU
CMK MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjBdVlKSzVyPUGuPVYyPTlizszN MX\TRW5ITVJ?
ST486 M2HhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjDfmZKSzVyPUKuOFMxPzNizszN NVm2doZtW0GQR1XS
CI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LZOmlEPTB;Mj60PVY2QSEQvF2= MnqyV2FPT0WU
KP-N-RT-BM-1 M4joTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJwN{CxNlIh|ryP MkPZV2FPT0WU
ALL-PO MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPQXYtKSzVyPUOuNVgzODdizszN NWn2cXN[W0GQR1XS
KS-1 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwMkGyNlUh|ryP MUnTRW5ITVJ?
Becker NHO0bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrSTWM2OD12LkKzPVMh|ryP MmTjV2FPT0WU
GDM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRwMkS2NVch|ryP NIi0c5ZUSU6JRWK=
BC-1 NFjRW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6WllmUUN3ME20MlQ6Ojd5IN88US=> NV:2UZFLW0GQR1XS
NB14 MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwOEO1NlQh|ryP NUHQdHV[W0GQR1XS
NOS-1 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnLd2xKSzVyPUWuN|M5PzRizszN MkjjV2FPT0WU
MZ1-PC MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzQTWM2OD13LkiyNVUyKM7:TR?= NWf4SWF7W0GQR1XS
A498 NEKwOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnFZ5JKSzVyPU[uNFg1PzNizszN MU\TRW5ITVJ?
EW-16 NUO0bpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELje|ZKSzVyPU[uN|c4PzNizszN MoLFV2FPT0WU
NALM-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPXTWM2OD14Lk[4N|g4KM7:TR?= NYP2[JB5W0GQR1XS
EB-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH0dpRKSzVyPUeuNFczOzNizszN NHO5W4lUSU6JRWK=
697 M4i0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkewTWM2OD17LkK0N|I6KM7:TR?= NWLqWpZZW0GQR1XS
Ramos-2G6-4C10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;nc2lEPTB;OT61PVg1OiEQvF2= MlfsV2FPT0WU
KNS-81-FD MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjrR4x2UUN3ME25MlY6PjV|IN88US=> NFm3UJRUSU6JRWK=
HUTU-80 M2XYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm4fotrUUN3ME25Mlc1PjR{IN88US=> M2TFdHNCVkeHUh?=
LS-411N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJNmlEPTB;MUCuNFU3PyEQvF2= MX3TRW5ITVJ?
RPMI-8402 NWDacFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HZN2lEPTB;MUCuNVE3KM7:TR?= MXXTRW5ITVJ?
KU812 M1XkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;xNGlEPTB;MUCuNlk6OSEQvF2= Mkf2V2FPT0WU
EW-1 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml64TWM2OD1zMD60OFI2KM7:TR?= MlnyV2FPT0WU
HC-1 M13pUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLBfVZKSzVyPUGwMlQ5PDRizszN M{D3dnNCVkeHUh?=
NB69 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rweGlEPTB;MUCuOVA1OyEQvF2= M3TNTnNCVkeHUh?=
MFH-ino NIHESndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHEWFlKSzVyPUGwMlg{ODNizszN NGmwWmVUSU6JRWK=
CCRF-CEM NIXPbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nKO2lEPTB;MUGuOVk4KM7:TR?= NIjncHhUSU6JRWK=
SK-N-DZ MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzkTWM2OD1zMj6wOFM3KM7:TR?= NG[y[GpUSU6JRWK=
NCI-H720 NXnNSVRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITvZ|JKSzVyPUGyMlE4ODVizszN M1XDd3NCVkeHUh?=
HCC1187 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG5eGxzUUN3ME2xNk4zODRzIN88US=> NVX3VnVDW0GQR1XS
IST-SL2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzaTWM2OD1zMj60PFczKM7:TR?= MX7TRW5ITVJ?
KE-37 NXHLW2k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPCfVZJUUN3ME2xNk44QTZ4IN88US=> NY\zW2MzW0GQR1XS
HCC1599 NHX5N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDHXI9KSzVyPUGyMlkxPjlizszN NGPGcmRUSU6JRWK=
A4-Fuk M3\KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2TWlEPTB;MUKuPVU5PiEQvF2= MWLTRW5ITVJ?
NKM-1 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF|LkK5NlUh|ryP MmPGV2FPT0WU
BE-13 NEHWTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYeyRm0xUUN3ME2xN{44QTh7IN88US=> MY\TRW5ITVJ?
MV-4-11 NXjqdIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHezXFRKSzVyPUG0MlA{OjRizszN M3q5dXNCVkeHUh?=
OPM-2 MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT4TWM2OD1zND60NFg2KM7:TR?= NX33V4xLW0GQR1XS
KARPAS-422 NVTvNndqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\yNWZ{UUN3ME2xOE42OTJ4IN88US=> NX;4PIRmW0GQR1XS
RPMI-8226 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\2W|RKSzVyPUG0Mlg6OTVizszN NFXufWxUSU6JRWK=
KARPAS-45 M2T5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF3Lke3NVYh|ryP MnnyV2FPT0WU
SK-PN-DW M4C3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DOb2lEPTB;MUWuPFY{OSEQvF2= MXnTRW5ITVJ?
LC-2 NEPiXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe4dHpQUUN3ME2xOk4yPTB4IN88US=> NWDVb|lnW0GQR1XS
NCI-H1648 NFXnS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG1SWVMUUN3ME2xOk4zPTRizszN NHfKSlVUSU6JRWK=
RL95-2 NEC5OppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXyZmxqUUN3ME2xOk4{QTd6IN88US=> NWLPPHBjW0GQR1XS
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m0[WlEPTB;MU[uO|I4PCEQvF2= MmHCV2FPT0WU
RPMI-6666 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF4LkmyNVEh|ryP NXTXVmJwW0GQR1XS
SIG-M5 NFXx[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXvWZVLUUN3ME2xO{4yQTB|IN88US=> MnvaV2FPT0WU
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5Lke0OVEh|ryP MVnTRW5ITVJ?
MONO-MAC-6 NFTkVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3aTWM2OD1zNz65N|EzKM7:TR?= MljRV2FPT0WU
LAN-6 NGTifYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX6boJKUUN3ME2xPE44PTV5IN88US=> NV7wZ3diW0GQR1XS
A388 MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L5VWlEPTB;MUmuN|A2QSEQvF2= NW\kRXF[W0GQR1XS
SK-NEP-1 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJyLkKxN|Ih|ryP NH\y[ZJUSU6JRWK=
TE-10 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\5e2lKSzVyPUKwMlUzOjFizszN M2rLbnNCVkeHUh?=
HL-60 M3P3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtenlKUUN3ME2yNE46ODl7IN88US=> MVHTRW5ITVJ?
MC116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJzLkeyNlEh|ryP MWnTRW5ITVJ?
SW962 M4nh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLCZYhKSzVyPUKxMlc6OTVizszN NG\SV|BUSU6JRWK=
NOMO-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSzTWM2OD1{Mj62OVY1KM7:TR?= MVLTRW5ITVJ?
CTB-1 NGLVUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXWV5VmUUN3ME2yNk45PjdzIN88US=> NGnBeJBUSU6JRWK=
MRK-nu-1 NIj3S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HEUWlEPTB;MkKuPVA4PCEQvF2= MoH0V2FPT0WU
GR-ST MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfVTWM2OD1{Mz63OkDPxE1? M2n6cXNCVkeHUh?=
HH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDYdW9KSzVyPUK0MlAxOyEQvF2= MVHTRW5ITVJ?
NCI-H1963 NE\ieVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ2LkC3PFIh|ryP NYDDNHVoW0GQR1XS
QIMR-WIL M3XPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fSbWlEPTB;MkSuPFc4OiEQvF2= Mk\ZV2FPT0WU
CGTH-W-1 NEfZVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ3LkC3NlMh|ryP MoD3V2FPT0WU
LP-1 M3\6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jPNmlEPTB;MkWuOlU2OSEQvF2= Mn\EV2FPT0WU
NCI-H748 M3nM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHUcWhKSzVyPUK2MlUyOzdizszN NGDSXpJUSU6JRWK=
PF-382 NXzNVlZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW5d2U6UUN3ME2yO{4zOjJ|IN88US=> MlezV2FPT0WU
ATN-1 M1z4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrFXIlKSzVyPUK3MlM4OzJizszN NEnHe5FUSU6JRWK=
L-540 M{jEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq5UmFvUUN3ME2yO{43PDV7IN88US=> NGjibWVUSU6JRWK=
LXF-289 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ5Lke1NVkh|ryP MUPTRW5ITVJ?
LS-513 NEfwZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe4UnBDUUN3ME2yPE4yQDB5IN88US=> MkHPV2FPT0WU
NCI-H1581 NWfBSHB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn3d5J4UUN3ME2zNE4{QTd4IN88US=> NEXWW3VUSU6JRWK=
ES6 NFvtTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4O2lEPTB;M{CuOlg6QSEQvF2= Ml\0V2FPT0WU
SW982 NVX0[YY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnHTIVKSzVyPUOwMlg2PjZizszN NIruT2dUSU6JRWK=
DOHH-2 NGrpTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmwVZNCUUN3ME2zNU42QDl|IN88US=> M4DybHNCVkeHUh?=
DB M2L3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN|Lkm0N|Eh|ryP MnHMV2FPT0WU
MPP-89 M37mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nSdGlEPTB;M{SuNVc2PiEQvF2= NV[xb2FIW0GQR1XS
LB831-BLC NVLtcJVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3qc3ZKSzVyPUO0MlUyQDRizszN NH3NToFUSU6JRWK=
NB5 NEXzeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HTWM2OD1|ND64OVM2KM7:TR?= MVTTRW5ITVJ?
GB-1 NXKzNFhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HTcGlEPTB;M{WuNFQ3QSEQvF2= MlP5V2FPT0WU
TE-15 NHWzdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7mUpZXUUN3ME2zOU4zOjN6IN88US=> MYrTRW5ITVJ?
LC4-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Pke2lEPTB;M{WuN|g1PyEQvF2= NYTuOXBFW0GQR1XS
NCI-H747 NG\qeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDDTWM2OD1|Nj6xN|Y6KM7:TR?= MljMV2FPT0WU
NTERA-S-cl-D1 M1yzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTN6LkezOFch|ryP NH7hSWZUSU6JRWK=
SK-MM-2 NXrTR|IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LPbmlEPTB;NECuNVE1PiEQvF2= NU\BPFZqW0GQR1XS
TGW M2nsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX3W3FKSzVyPUSxMlA2PjNizszN NIr5ZlJUSU6JRWK=
ONS-76 NX3aUlk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjYW2dCUUN3ME20Nk41QDh|IN88US=> MVLTRW5ITVJ?
CPC-N NHfSbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTGbmpUUUN3ME20Nk46QTdzIN88US=> Mn\kV2FPT0WU
ES4 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fFe2lEPTB;NESuOFE2OyEQvF2= MX3TRW5ITVJ?
Daudi NULWcW0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLpRWxKSzVyPUS1MlA5OjdizszN NUK5[IVCW0GQR1XS
MOLT-4 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR3LkC4OVMh|ryP MWXTRW5ITVJ?
HT-144 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD12Nj63NlYh|ryP NYT6Z45vW0GQR1XS
SW872 M33J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPyNIZKUUN3ME20PE4yQTN|IN88US=> M3r1UHNCVkeHUh?=
D-283MED NG\TdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR6LkO1OFIh|ryP M1T3NnNCVkeHUh?=
NCI-H2126 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR6Lki0O|Yh|ryP Mn\aV2FPT0WU
NCI-SNU-16 M3PM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR7LkKxOFMh|ryP NFH3T3JUSU6JRWK=
CESS Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O3cGlEPTB;NEmuOVA5QCEQvF2= NFfIcllUSU6JRWK=
A101D MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[yTWM2OD12OT65O|M3KM7:TR?= NG\Fco5USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
細胞アッセイ: [1]
+ 展開
  • 細胞株: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • 濃度: 0-256 nM
  • 反応時間: 1 hour
  • 実験の流れ: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 5% DMSO+30% PEG 300+dd H2O 5mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 450.34
化学式

C21H22Cl2FN5O

CAS No. 877399-52-5
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met信号経路図

c-Met Inhibitors with Unique Features

相関c-Met製品

Tags: Crizotinib (PF-02341066)を買う | Crizotinib (PF-02341066) ic50 | Crizotinib (PF-02341066)供給者 | Crizotinib (PF-02341066)を購入する | Crizotinib (PF-02341066)費用 | Crizotinib (PF-02341066)生産者 | オーダーCrizotinib (PF-02341066) | Crizotinib (PF-02341066)化学構造 | Crizotinib (PF-02341066)分子量 | Crizotinib (PF-02341066)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID